Fractyl-Logo-CMYK-June2021-02Fractyl Health announced today that it received FDA approval for an investigational device exemption (IDE) trial of its diabetes reversal platform.

Lexington, Massachusetts-based Fractyl Health will evaluate its Revita treatment in patients with type 2 diabetes whose disease is inadequately controlled despite treatment with at least two antidiabetic agents (ADAs) and who are not yet on insulin in the Revitalize-2 IDE pivotal study.

Get the full story at our sister site, Drug Delivery Business News.